NASDAQ:BGNE

BeiGene - BGNE Stock Forecast, Price & News

$194.57

+2.96 (+1.54%)

(As of 12/1/2022 12:00 AM ET)

Add

Compare

Today's Range: $188.32
▼
$197.84
50-Day Range: $125.51
▼
$207.71
52-Week Range: $118.18
▼
$365.16

Volume: 284,746 shs
Average Volume: 283,458 shs
Market Capitalization: $20.20 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $239.50

BeiGene MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 23.1% Upside
$239.50 Price Target
Short Interest: Healthy
1.99% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.37
Based on 4 Articles This Week
Insider Trading: Selling Shares
$10.27 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($17.69) to ($12.51) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

905th out of 1,047 stocks

Pharmaceutical Preparations Industry

441st out of 512 stocks

2.5

Analyst's Opinion

Consensus Rating
BeiGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $239.50, BeiGene has a forecasted upside of 23.1% from its current price of $194.57.
Amount of Analyst Coverage
BeiGene has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.99% of the outstanding shares of BeiGene have been sold short.
Short Interest Ratio / Days to Cover
BeiGene has a short interest ratio ("days to cover") of 8.7.
Change versus previous month
Short interest in BeiGene has recently decreased by 3.72%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
BeiGene does not currently pay a dividend.
Dividend Growth
BeiGene does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BGNE.

1.9

News and Social Media Coverage

News Sentiment
BeiGene has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for BeiGene this week, compared to 6 articles on an average week.
Search Interest
Only 8 people have searched for BGNE on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
MarketBeat Follows
9 people have added BeiGene to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BeiGene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,273,368.00 in company stock.
Percentage Held by Insiders
Only 7.50% of the stock of BeiGene is held by insiders.
Percentage Held by Institutions
51.77% of the stock of BeiGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BeiGene are expected to grow in the coming year, from ($17.69) to ($12.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BeiGene is -9.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BeiGene is -9.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BeiGene has a P/B Ratio of 4.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BeiGene (NASDAQ:BGNE) Stock

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock News Headlines

December 1, 2022 | finance.yahoo.com

Why Shares of BeiGene Were Up Wednesday

November 27, 2022 | finance.yahoo.com

In the wake of BeiGene, Ltd.'s (NASDAQ:BGNE) latest US$2.9b market cap drop, institutional owners may be forced to take severe actions

November 25, 2022 | markets.businessinsider.com

SVB Securities Keeps Their Buy Rating on BeiGene (BGNE)

November 24, 2022 | americanbankingnews.com

BeiGene (NASDAQ:BGNE) Trading Down 5.6%

November 22, 2022 | finance.yahoo.com

BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022

November 22, 2022 | americanbankingnews.com

Brokers Set Expectations for BeiGene, Ltd.'s FY2022 Earnings (NASDAQ:BGNE)

November 17, 2022 | finance.yahoo.com

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)

November 10, 2022 | finance.yahoo.com

BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers

November 4, 2022 | finance.yahoo.com

BeiGene to Present at Upcoming Investor Conferences

November 3, 2022 | finance.yahoo.com

BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting

November 3, 2022 | finance.yahoo.com

Is This Chinese Pharmaceutical Stock Worth the Risk?

November 2, 2022 | finance.yahoo.com

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

October 19, 2022 | finance.yahoo.com

AnHeart Therapeutics Expands US Team with Appointments in Clinical Research and Medical Affairs - Yahoo Finance

October 18, 2022 | benzinga.com

New Drugs Approvals Bring No Relief for Ailing Innovent Bio - BeiGene (NASDAQ:BGNE), Eli Lilly (NYSE:LLY) - Benzinga

October 18, 2022 | finance.yahoo.com

ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site - Yahoo Finance

October 17, 2022 | finance.yahoo.com

Investors ignore increasing losses at BeiGene (NASDAQ:BGNE) as stock jumps 16% this past week - Yahoo Finance

October 17, 2022 | finance.yahoo.com

Investors ignore increasing losses at BeiGene (NASDAQ:BGNE) as stock jumps 16% this past week

October 15, 2022 | marketwatch.com

BeiGene Gets Positive CHMP Opinion for Brukinsa for Chronic Lymphocytic Leukemia - MarketWatch

October 14, 2022 | benzinga.com

BeiGene shares are trading higher after the company announced the CHMP of the European Medicines Agency issued a positive opinion recommending approval of BRUKINSA for the treatment of adult patients with chronic lymphocytic leukemia. - BeiGene ( - Benzinga

October 14, 2022 | finance.yahoo.com

European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting

October 14, 2022 | marketwatch.com

BeiGene Says Brukinsa Drug Bested Rival at Trial - MarketWatch

October 14, 2022 | businesswire.com

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL - Business Wire

October 14, 2022 | seekingalpha.com

BeiGene Brukinsa shows better survival vs Imbruvica in blood cancer patients in trial - Seeking Alpha

October 14, 2022 | nasdaq.com

BeiGene: CHMP Issues Positive Opinion Recommending Approval Of BRUKINSA - Quick Facts - Nasdaq

October 14, 2022 | finance.yahoo.com

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Company Calendar

Last Earnings: 11/04/2021
Today: 12/01/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/24/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BGNE
CUSIP: N/A
CIK: 1651308
Web: www.beigene.com
Phone: 861085148500
Fax: N/A
Employees: 8,200
Year Founded: 2010

Price Target and Rating

Average Stock Price Forecast: $239.50
High Stock Price Forecast: $296.00
Low Stock Price Forecast: $210.00
Forecasted Upside/Downside: +23.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($21.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,413,350,000.00
Net Margins: -171.94%
Pretax Margin: -169.38%
Return on Equity: -38.92%
Return on Assets: -27.93%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 4.07
Quick Ratio: 3.87

Sales & Book Value

Annual Sales: $1.18 billion
Price / Sales: 17.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $44.84 per share
Price / Book: 4.34

Miscellaneous

Outstanding Shares: 103,818,000
Free Float: 96,032,000
Market Cap: $20.20 billion
Optionable: Optionable
Beta: 0.82

Social Links

Key Executives

Mr. John V. Oyler (Age 54)
Co-Founder, Exec. Chairman & CEO
Comp: $1.75M

Dr. Xiaobin Wu Ph.D. (Age 60)
Pres, COO & GM of China
Comp: $1.64M

Dr. Xiaodong Wang Ph.D. (Age 59)
Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director
Comp: $250k

Ms. Julia Wang (Age 51)
CFO & Principal Accounting Officer
Comp: $798.14k

Mr. Wang Lai (Age 45)
Global Head of R&D
Comp: $1.13M

Dr. Edna Huang M.D. (Age 49)
Consultant
Comp: $768.08k

Mr. Daniel Maller
VP of Fin. & Accounting

Ms. Mi Zhou
Sr. Director of Investor Relations

Mr. Kevin C. Mannix
Sr. VP of Investor Relations.

Ms. Diana Lee Francis
VP and Global Head of Quality & Regulatory Compliance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BGNE Stock - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.
What is BeiGene's stock price forecast for 2023?: 5 analysts have issued 12 month target prices for BeiGene's stock. Their BGNE share price forecasts range from $210.00 to $296.00. On average, they expect the company's share price to reach $239.50 in the next year. This suggests a possible upside of 23.1% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.
How have BGNE shares performed in 2022?: BeiGene's stock was trading at $270.93 at the start of the year. Since then, BGNE shares have decreased by 28.2% and is now trading at $194.57.
View the best growth stocks for 2022 here.
When is BeiGene's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our BGNE earnings forecast.
How were BeiGene's earnings last quarter?: BeiGene, Ltd. (NASDAQ:BGNE) announced its earnings results on Thursday, November, 4th. The company reported ($4.46) earnings per share for the quarter, topping the consensus estimate of ($4.70) by $0.24. The firm had revenue of $206.44 million for the quarter, compared to analyst estimates of $185.70 million. BeiGene had a negative trailing twelve-month return on equity of 38.92% and a negative net margin of 171.94%.
What is John V. Oyler's approval rating as BeiGene's CEO?: 58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).
When did BeiGene IPO?: (BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.
What is BeiGene's stock symbol?: BeiGene trades on the NASDAQ under the ticker symbol "BGNE."
Who are BeiGene's major shareholders?: BeiGene's stock is owned by a number of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (4.57%), Baillie Gifford & Co. (3.10%), Temasek Holdings Private Ltd (3.00%), BlackRock Inc. (2.69%), State Street Corp (0.72%) and Price T Rowe Associates Inc. MD (0.43%). Insiders that own company stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends.
How do I buy shares of BeiGene?: Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BeiGene's stock price today?: One share of BGNE stock can currently be purchased for approximately $194.57.
How much money does BeiGene make?: BeiGene (NASDAQ:BGNE) has a market capitalization of $20.20 billion and generates $1.18 billion in revenue each year. The company earns $-1,413,350,000.00 in net income (profit) each year or ($21.35) on an earnings per share basis.
How many employees does BeiGene have?: The company employs 8,200 workers across the globe.
How can I contact BeiGene?: BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at 861085148500 or via email at ir@beigene.com.

This page (NASDAQ:BGNE) was last updated on 12/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial